Browsing Tag
The Lancet
5 posts
ScreenPoint Medical bets on risk prediction and workflow AI after $16m funding boost
ScreenPoint Medical has raised $16 million to expand its breast imaging AI platform. Read why this funding could reshape screening and risk prediction.
Corcept Therapeutics (CORT) stock in focus as ROSELLA survival data strengthen Lifyorli launch in ovarian cancer
Corcept Therapeutics strengthened its Lifyorli launch with new ROSELLA survival data. Read what this means for CORT stock and ovarian cancer treatment.
Breakthrough results: Intensity Therapeutics’ INT230-6 delivers strong survival and immune response in phase 1/2 cancer trial
Find out how Intensity Therapeutics’ INT230-6 achieved 11.9-month survival and immune activation in metastatic cancer—read what this means for biotech investors.
Resmed earnings soar—Is this sleep tech giant the next big health stock to watch?
Find out how Resmed’s Q3 FY25 results and stock surge signal strength in the sleep tech market. Explore the bullish sentiment and investor strategy.
MeiraGTx’s rAAV8.hRKp.AIPL1 shows remarkable efficacy in treating severe retinal dystrophy
A gene therapy developed by MeiraGTx Holdings plc has demonstrated remarkable success in restoring vision to children born…